These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21087499)

  • 1. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491.
    Filippi L; Cavallaro G; Fiorini P; Daniotti M; Benedetti V; Cristofori G; Araimo G; Ramenghi L; La Torre A; Fortunato P; Pollazzi L; la Marca G; Malvagia S; Bagnoli P; Ristori C; Dal Monte M; Bilia AR; Isacchi B; Furlanetto S; Tinelli F; Cioni G; Donzelli G; Osnaghi S; Mosca F
    BMC Pediatr; 2010 Nov; 10():83. PubMed ID: 21087499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial.
    Filippi L; Cavallaro G; Berti E; Padrini L; Araimo G; Regiroli G; Bozzetti V; De Angelis C; Tagliabue P; Tomasini B; Buonocore G; Agosti M; Bossi A; Chirico G; Aversa S; Pasqualetti R; Fortunato P; Osnaghi S; Cavallotti B; Vanni M; Borsari G; Donati S; Nascimbeni G; la Marca G; Forni G; Milani S; Cortinovis I; Bagnoli P; Dal Monte M; Calvani AM; Pugi A; Villamor E; Donzelli G; Mosca F
    BMC Pediatr; 2017 Jul; 17(1):165. PubMed ID: 28709412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives.
    Filippi L; Cavallaro G; Bagnoli P; Dal Monte M; Fiorini P; Donzelli G; Tinelli F; Araimo G; Cristofori G; la Marca G; Della Bona ML; La Torre A; Fortunato P; Furlanetto S; Osnaghi S; Mosca F
    J Pediatr; 2013 Dec; 163(6):1570-1577.e6. PubMed ID: 24054431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of propranolol in very preterm infants at the risk of retinopathy of prematurity: Which newborn and when?
    Ozturk MA; Korkmaz L
    Int Ophthalmol; 2019 Sep; 39(9):1921-1930. PubMed ID: 30229439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index.
    Korkmaz L; Baştuğ O; Ozdemir A; Korkut S; Karaca C; Akin MA; Gunes T; Kurtoglu S; Ozturk MA
    Curr Eye Res; 2017 Jan; 42(1):88-97. PubMed ID: 27260268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial.
    Bührer C; Erdeve Ö; Bassler D; Bar-Oz B
    BMJ Open; 2018 Jul; 8(7):e021749. PubMed ID: 29982217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial.
    Filippi L; Cavallaro G; Bagnoli P; Dal Monte M; Fiorini P; Berti E; Padrini L; Donzelli G; Araimo G; Cristofori G; Fumagalli M; la Marca G; Della Bona ML; Pasqualetti R; Fortunato P; Osnaghi S; Tomasini B; Vanni M; Calvani AM; Milani S; Cortinovis I; Pugi A; Agosti M; Mosca F
    Pediatr Res; 2017 Feb; 81(2):307-314. PubMed ID: 27814346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral propranolol in early stages of retinopathy of prematurity.
    Bancalari A; Schade R; Muñoz T; Lazcano C; Parada R; Peña R
    J Perinat Med; 2016 Jul; 44(5):499-503. PubMed ID: 26845715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term Refractive Effects of Propranolol Hydrochloride Prophylaxis on Retinopathy of Prematurity in Very Preterm Newborns.
    Korkmaz L; Karaca C; Akin MA; Bastug O; Sahiner M; Ozdemir A; Gunes T; Ozturk MA; Kurtoglu S
    Curr Eye Res; 2018 Feb; 43(2):213-217. PubMed ID: 29135357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study.
    Filippi L; Cavallaro G; Berti E; Padrini L; Araimo G; Regiroli G; Raffaeli G; Bozzetti V; Tagliabue P; Tomasini B; Mori A; Buonocore G; Agosti M; Bossi A; Chirico G; Aversa S; Fortunato P; Osnaghi S; Cavallotti B; Suzani M; Vanni M; Borsari G; Donati S; Nascimbeni G; Nardo D; Piermarocchi S; la Marca G; Forni G; Milani S; Cortinovis I; Calvani M; Bagnoli P; Dal Monte M; Calvani AM; Pugi A; Villamor E; Donzelli G; Mosca F
    Front Pediatr; 2019; 7():180. PubMed ID: 31134171
    [No Abstract]   [Full Text] [Related]  

  • 11. Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy.
    Chen J; Joyal JS; Hatton CJ; Juan AM; Pei DT; Hurst CG; Xu D; Stahl A; Hellstrom A; Smith LE
    Invest Ophthalmol Vis Sci; 2012 May; 53(6):2968-77. PubMed ID: 22491401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinopathy of Prematurity: Therapeutic Strategies Based on Pathophysiology.
    Cayabyab R; Ramanathan R
    Neonatology; 2016; 109(4):369-76. PubMed ID: 27251645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Propranolol in Preventing Severe Retinopathy of Prematurity: A Comprehensive Systematic Review and Meta-Analysis.
    Shafique MA; Haseeb A; Uddin MMN; Asghar B; Chaudhry ER; Raqib MA; Ali SMS; Mustafa MS
    Am J Ophthalmol; 2024 Mar; 259():141-150. PubMed ID: 37979602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update in the Treatment of Retinopathy of Prematurity.
    Bancalari A; Schade R
    Am J Perinatol; 2022 Jan; 39(1):22-30. PubMed ID: 32544962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retinopathy of the premature: Update in screening and treatment].
    Bancalari M A; Schade R
    Rev Chil Pediatr; 2020 Feb; 91(1):122-130. PubMed ID: 32730423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system.
    Filippi L; Dal Monte M; Casini G; Daniotti M; Sereni F; Bagnoli P
    Med Res Rev; 2015 May; 35(3):619-52. PubMed ID: 25523517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice.
    Dal Monte M; Casini G; la Marca G; Isacchi B; Filippi L; Bagnoli P
    Exp Eye Res; 2013 Jun; 111():27-35. PubMed ID: 23528535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic propranolol for prevention of ROP and visual outcome at 1 year (PreROP trial).
    Sanghvi KP; Kabra NS; Padhi P; Singh U; Dash SK; Avasthi BS
    Arch Dis Child Fetal Neonatal Ed; 2017 Sep; 102(5):F389-F394. PubMed ID: 28087723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinopathy of prematurity in infants weighing less than 500 grams at birth enrolled in the early treatment for retinopathy of prematurity study.
    Wheeler DT; Dobson V; Chiang MF; Bremer DL; Gewolb IH; Phelps DL; Hardy RJ; Good WV; Fellows R; Tung BP; Palmer EA
    Ophthalmology; 2011 Jun; 118(6):1145-51. PubMed ID: 21211840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.